Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases
- 5 October 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (23), 5793-5797
- https://doi.org/10.1016/j.bmcl.2004.09.042
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for TreatmentMini-Reviews in Medicinal Chemistry, 2004
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- The Protein Kinase Complement of the Human GenomeScience, 2002
- The Conformational Plasticity of Protein KinasesCell, 2002
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid CellsPublished by Elsevier ,1997
- Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivativesBioorganic & Medicinal Chemistry Letters, 1997
- Bcr/Abl expression stimulates integrin function in hematopoietic cell lines.Journal of Clinical Investigation, 1996
- Synthesis and antiinflammatory activity of trisubstituted pyrimidines and triazinesJournal of Medicinal Chemistry, 1978